Danish biotech firm Zealand Pharma proposes former Novo Nordisk senior to board
COPENHAGEN, May 1 (Reuters) - Danish biotech firm Zealand Pharma ZELA.CO said on Friday it proposed to elect Camilla Sylvest, previous head of commercial strategy and corporate affairs at Wegovy maker Novo Nordisk NOVOb.CO, to its board of directors at an extraordinary general meeting later this month. (Reporting by Louise Rasmussen, Editing by Louise Heavens) ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)